Skip to content
Home/Companies/Biotech/DBV

DBV

Biotech·France·Exited 2014·Held 4yr
Entry
2010
Hold
4yr
Exit
2014

Who owns DBV?

DBV is a French Biotech company, formerly owned by Sofinnova Partners, exited in 2014 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VI · 2008 · Life Sciences VC

Key facts

HQFrance
SectorBiotech
Exit Type
IPO
Exit Year
2014

More from Sofinnova Capital VI

Other portfolio companies in the same fund.

ABIONYX Pharma
Exited 2020
BiotechFrance· 2010
Omthera Pharmaceuticals
Exited 2013
BiotechUS· 2010
to AstraZeneca
Ablynx NV
Exited 2018
BiotechBelgium· 2008
to Sanofi
Addex Therapeutics
Exited 2012
BiotechSwitzerland· 2008
Movetis
Exited 2010
BiotechBelgium· 2008
to Shire
Noxxon Pharma
Exited 2016
BiotechGermany· 2008

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns DBV?

DBV was formerly owned by Sofinnova Partners, exited in 2014. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue